Antonio Passaro: Discussing the latest evidences on NSCLC harbouring EGFR mutations at ESMO24
Antonio Passaro shared a post on LinkedIn:
“Join us at ESMO24 on Sunday, Sep 15, for our symposium to discuss the latest evidences on NSCLC harbouring EGFR mutations
The session will be great – with a stellar faculty Enriqueta Felip, Noemi Reguart, MD, PhD Sanjay Popat, Alex Spira, MD, PhD, FACP, FASCO and me.
Mark your calendar & hope to see you there.”
Source: Antonio Passaro/LinkedIn
Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. he focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC). Dr. Antonio Passaro is an Associate Editor for Lung Cancer Journal by Elsevier and the Chair of the ESMO Press & Media Affairs Committee. He is also a faculty member for the Lung and Other Thoracic Tumours faculty group and the ESMO-MCBS Extended Working Group. He also holds editorial positions and key roles in societies like ESMO and AIOM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023